157 - Respiratory Viruses: The Big 3

Friday, October 18, 2024

1:45 PM – 3:00 PM US PT

Location: Petree C

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Christine Johnston, MD, MPH (she/her/hers)

Associate Professor
Medicine
University of Washington
Seattle, WA, United States
Angela R. Branche, MD, MD (she/her/hers)

Associate Professor of Medicine
University of Rochester
Rochester, NY, United States

Faculty(s)

AB

Adarsh Bhimraj, MD

Director, ID fellowship programs and education
Houston Methodist Hospital, TX, United States
Hana El Sahly, MD

Professor, Molecular Virology and Microbiology
Baylor College of Medicine
HT

H. Keipp Talbot, MD, MPH

Professor
Vanderbilt University
Nashville, TN, United States

Disclosure(s):

Christine Johnston, MD, MPH: Assembly Bioscience: Advisor/Consultant (Ongoing); Gilead Biosciences: Grant/Research Support (Terminated, December 31, 2022); GSK: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Moderna, Inc.: Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing)

Angela R. Branche, MD, MD: Cyanvac: Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); Moderna, Inc.: Grant/Research Support (Ongoing); Pfizer, Inc.: Grant/Research Support (Ongoing); Sanofi Pasteur LLC: Advisor/Consultant (Ongoing); Vaccitech: Grant/Research Support (Ongoing)

Adarsh Bhimraj, MD: No financial relationships to disclose

Hana M. El Sahly, MD: No financial relationships to disclose

H. Keipp Talbot, MD, MPH: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the current covid-19 treatment guidelines for inpatient and outpatient treatment;
identify novel strategies in the pipeline to prevent and treat influenza infection;
recognize the impact that rsv prevention tools will have on rsv related morbidity.

Presentations:

1:45 PM – 2:10 PM US PT

IDSA COVID-19 Treatment Guideline updates
Speaker: Adarsh Bhimraj, MD – Houston Methodist Hospital
2:10 PM – 2:35 PM US PT

New influenza countermeasures: What's coming?
Speaker: Hana M. El Sahly, MD – Baylor College of Medicine
2:35 PM – 3:00 PM US PT

RSV Prevention at 1 year
Speaker: H. Keipp Talbot, MD, MPH – Vanderbilt University